BMS 753493

Drug Profile

BMS 753493

Alternative Names: BMS-753493; Epofolate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb; Endocyte
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Epothilones; Heterocyclic bicyclo compounds
  • Mechanism of Action Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 01 Jul 2010 Bristol-Myers Squibb terminates phase I/II trial (NCT00546247) in late-stage Solid tumours in USA and Netherlands
  • 01 Jul 2010 Bristol-Myers Squibb terminates phase I/II trial (NCT00550017) in late-stage Solid tumours in USA, Canada and United Kingdom
  • 15 Nov 2009 Final pharmacodynamics data from a preclinical trial in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top